Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Indivior (Nasdaq: INDV) study supports 300 mg SUBLOCADE dose for fentanyl-heavy opioid use cases
Indivior’s new trial results highlight how higher-dose SUBLOCADE may better support fentanyl users in OUD treatment. See what this means for the industry.
PRISM BioLab and Talus Bioscience aim to crack the transcription factor code with dual-platform drug discovery strategy
PRISM BioLab and Talus Bio have teamed up to crack transcription factor drug discovery. Find out how their dual-platform strategy could reshape precision medicine.
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough?
Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect.
Vistagen shares topline PALISADE-3 Phase 3 data for fasedienol in acute social anxiety treatment
Find out how Vistagen’s PALISADE-3 Phase 3 results for fasedienol reshape its social anxiety strategy and investor expectations.
VYNE Therapeutics and Yarrow Bioscience merger signals strategic reset toward autoimmune thyroid therapeutics
Find out how VYNE Therapeutics’ merger with Yarrow Bioscience resets its strategy around a $200M-backed autoimmune thyroid disease pipeline.
NorthStrive Biosciences enters Phase III validation stage for AI-discovered drug compounds in metabolic disease research
Find out how NorthStrive Biosciences is advancing AI-driven drug discovery into Phase III biological validation for metabolic disease research.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now.
AstraZeneca and Daiichi Sankyo win FDA approval for Enhertu combo as new standard in HER2 mBC
Enhertu plus pertuzumab gets FDA approval for first-line HER2-positive mBC, setting a new standard in metastatic breast cancer care. Read what changes now.